Wafaa El-Sadr | November 30, 2020 | GlobeNewswire
Drs. Myron S. Cohen and Wafaa M. El-Sadr, principal investigators of the HIV Prevention Trials Network (HPTN), in collaboration with FHI 360, have received a seven-year award from the U.S. National Institutes of Health as part of the next funding cycle (2020-2027) for the Network. The core and protocol-specific funding will enable the HPTN to continue its HIV prevention research efforts focused on developing new biomedical prevention methods and optimizing the integration of proven biomedical, behavioral and structural interventions to achieve high-effectiveness and impact.
During this new funding cycle, the HPTN will focus on the following four priority areas:
- Identifying novel antiretroviral (ARV)-based methods and delivery systems for HIV prevention
- Developing multi-purpose technologies for HIV prevention as well as for contraception and prevention of other sexually transmitted infections
- Evaluating broadly neutralizing antibodies alone or in a combination that prevent HIV acquisition, in collaboration with the HIV Vaccine Trials Network
- Designing and conducting population-specific integrated strategy studies that combine biomedical, socio-behavioral, and structural interventions for HIV prevention to maximize their effectiveness
The HPTN will also continue as a partner in the COVID-19 Prevention Network (CoVPN). The recently-formed CoVPN evaluates biological agents, including vaccines and monoclonal antibodies, to prevent COVID-19.
Originally published by GlobalNewswire. Read the press release here.